| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Mucosal Resection | 27 | 2024 | 74 | 11.180 |
Why?
|
| Colonoscopy | 13 | 2024 | 239 | 3.850 |
Why?
|
| Colonic Polyps | 8 | 2024 | 78 | 3.270 |
Why?
|
| Colorectal Neoplasms | 10 | 2024 | 561 | 3.020 |
Why?
|
| Esophageal Neoplasms | 9 | 2024 | 359 | 2.980 |
Why?
|
| Adenoma | 6 | 2020 | 133 | 2.860 |
Why?
|
| Stomach Neoplasms | 11 | 2024 | 538 | 2.850 |
Why?
|
| Exocrine Pancreatic Insufficiency | 4 | 2024 | 34 | 2.780 |
Why?
|
| Adenocarcinoma | 10 | 2024 | 993 | 2.490 |
Why?
|
| Pancreatitis, Chronic | 6 | 2024 | 68 | 2.320 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2024 | 80 | 2.300 |
Why?
|
| Pancreatic Neoplasms | 10 | 2024 | 676 | 2.210 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2024 | 79 | 1.800 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 245 | 1.770 |
Why?
|
| Pancreatitis | 5 | 2021 | 129 | 1.590 |
Why?
|
| Pancreatic Cyst | 4 | 2021 | 30 | 1.570 |
Why?
|
| Gastrectomy | 5 | 2020 | 89 | 1.540 |
Why?
|
| Barrett Esophagus | 4 | 2022 | 340 | 1.410 |
Why?
|
| Endoscopy, Gastrointestinal | 8 | 2024 | 243 | 1.400 |
Why?
|
| Early Detection of Cancer | 6 | 2020 | 348 | 1.280 |
Why?
|
| Gastric Mucosa | 5 | 2024 | 485 | 1.270 |
Why?
|
| Humans | 95 | 2024 | 123095 | 1.090 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2019 | 25 | 1.090 |
Why?
|
| Endoscopy, Digestive System | 4 | 2021 | 153 | 1.000 |
Why?
|
| Operative Time | 3 | 2024 | 160 | 0.980 |
Why?
|
| Treatment Outcome | 26 | 2024 | 12115 | 0.960 |
Why?
|
| Esophagoscopy | 5 | 2024 | 156 | 0.950 |
Why?
|
| Myotomy | 5 | 2024 | 18 | 0.910 |
Why?
|
| Retrospective Studies | 28 | 2024 | 16044 | 0.900 |
Why?
|
| Middle Aged | 33 | 2024 | 25990 | 0.890 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 121 | 0.880 |
Why?
|
| Fundoplication | 1 | 2024 | 66 | 0.870 |
Why?
|
| Colonic Diseases | 1 | 2023 | 38 | 0.860 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3011 | 0.820 |
Why?
|
| Colon | 2 | 2022 | 352 | 0.820 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 284 | 0.800 |
Why?
|
| Endosonography | 6 | 2022 | 81 | 0.800 |
Why?
|
| Aged | 25 | 2024 | 19092 | 0.790 |
Why?
|
| Sutures | 2 | 2022 | 67 | 0.790 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 97 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1118 | 0.750 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 19 | 0.740 |
Why?
|
| Esophagectomy | 1 | 2021 | 60 | 0.730 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 289 | 0.720 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 823 | 0.720 |
Why?
|
| Natural Orifice Endoscopic Surgery | 5 | 2024 | 70 | 0.710 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 115 | 0.710 |
Why?
|
| Male | 42 | 2024 | 60126 | 0.710 |
Why?
|
| Biopsy, Needle | 1 | 2021 | 229 | 0.700 |
Why?
|
| Suture Techniques | 1 | 2021 | 196 | 0.700 |
Why?
|
| Crohn Disease | 1 | 2023 | 281 | 0.690 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 771 | 0.690 |
Why?
|
| Female | 41 | 2024 | 65511 | 0.680 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2021 | 23 | 0.680 |
Why?
|
| Endoscopy | 3 | 2023 | 282 | 0.680 |
Why?
|
| Catheter Ablation | 1 | 2022 | 233 | 0.670 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 100 | 0.670 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 109 | 0.670 |
Why?
|
| Gastric Stump | 1 | 2019 | 1 | 0.660 |
Why?
|
| Prospective Studies | 15 | 2024 | 6028 | 0.650 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 239 | 0.640 |
Why?
|
| Indomethacin | 1 | 2019 | 84 | 0.640 |
Why?
|
| Stents | 4 | 2023 | 877 | 0.620 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 214 | 0.620 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 2847 | 0.620 |
Why?
|
| Cholangitis | 2 | 2016 | 32 | 0.620 |
Why?
|
| Pancreatic Diseases | 3 | 2023 | 39 | 0.610 |
Why?
|
| Helicobacter pylori | 3 | 2023 | 1315 | 0.610 |
Why?
|
| Helicobacter Infections | 3 | 2023 | 1257 | 0.600 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 13 | 0.600 |
Why?
|
| Quality of Life | 4 | 2024 | 1923 | 0.590 |
Why?
|
| Malabsorption Syndromes | 1 | 2018 | 36 | 0.580 |
Why?
|
| Pancreas | 6 | 2023 | 211 | 0.580 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1213 | 0.570 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 29 | 0.560 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 117 | 0.550 |
Why?
|
| Needles | 1 | 2017 | 51 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 73 | 0.550 |
Why?
|
| Sensitivity and Specificity | 6 | 2024 | 2011 | 0.540 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6374 | 0.540 |
Why?
|
| Intestinal Polyps | 2 | 2024 | 29 | 0.530 |
Why?
|
| Feces | 2 | 2018 | 709 | 0.530 |
Why?
|
| Biopsy | 2 | 2021 | 1236 | 0.520 |
Why?
|
| Dissection | 3 | 2021 | 52 | 0.520 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 400 | 0.510 |
Why?
|
| Pyloric Antrum | 1 | 2015 | 64 | 0.500 |
Why?
|
| Common Bile Duct | 1 | 2015 | 14 | 0.500 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 47 | 0.490 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 38 | 0.490 |
Why?
|
| Esophageal Achalasia | 3 | 2024 | 37 | 0.490 |
Why?
|
| Adult | 17 | 2024 | 29008 | 0.470 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 77 | 0.470 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 13 | 0.470 |
Why?
|
| Gastroparesis | 1 | 2015 | 66 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 1071 | 0.460 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 271 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1258 | 0.450 |
Why?
|
| Quality of Health Care | 1 | 2017 | 391 | 0.440 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 151 | 0.430 |
Why?
|
| Margins of Excision | 2 | 2024 | 51 | 0.420 |
Why?
|
| Fluid Therapy | 2 | 2019 | 121 | 0.420 |
Why?
|
| Metaplasia | 3 | 2022 | 215 | 0.420 |
Why?
|
| Cholagogues and Choleretics | 1 | 2012 | 25 | 0.410 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2012 | 37 | 0.410 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2012 | 5 | 0.410 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 20 | 0.410 |
Why?
|
| Esophageal Motility Disorders | 2 | 2024 | 13 | 0.410 |
Why?
|
| Colic | 1 | 2012 | 9 | 0.410 |
Why?
|
| Gallstones | 1 | 2012 | 20 | 0.400 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2012 | 54 | 0.390 |
Why?
|
| Pilot Projects | 4 | 2024 | 1389 | 0.380 |
Why?
|
| Mediastinum | 1 | 2011 | 41 | 0.370 |
Why?
|
| Bacteremia | 1 | 2015 | 404 | 0.370 |
Why?
|
| Financing, Government | 1 | 2011 | 30 | 0.370 |
Why?
|
| Feasibility Studies | 4 | 2024 | 756 | 0.360 |
Why?
|
| Research Support as Topic | 1 | 2011 | 63 | 0.360 |
Why?
|
| Birth Weight | 1 | 2012 | 336 | 0.350 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 196 | 0.320 |
Why?
|
| Colonoscopes | 1 | 2009 | 9 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 604 | 0.290 |
Why?
|
| Microscopy, Confocal | 2 | 2019 | 348 | 0.290 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 83 | 0.290 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2018 | 52 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 334 | 0.290 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 507 | 0.280 |
Why?
|
| Tumor Burden | 2 | 2017 | 230 | 0.270 |
Why?
|
| Risk Factors | 6 | 2024 | 10018 | 0.270 |
Why?
|
| MicroRNAs | 2 | 2023 | 827 | 0.260 |
Why?
|
| Paclitaxel | 2 | 2024 | 120 | 0.260 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3234 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2024 | 3325 | 0.250 |
Why?
|
| Delphi Technique | 2 | 2024 | 202 | 0.250 |
Why?
|
| Biomedical Research | 1 | 2011 | 516 | 0.240 |
Why?
|
| Electrosurgery | 1 | 2024 | 19 | 0.230 |
Why?
|
| Gels | 1 | 2024 | 60 | 0.220 |
Why?
|
| Esophageal Stenosis | 1 | 2024 | 44 | 0.220 |
Why?
|
| Pancreatic Ducts | 2 | 2022 | 22 | 0.220 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 29 | 0.220 |
Why?
|
| Glycosides | 1 | 2023 | 7 | 0.220 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 71 | 0.220 |
Why?
|
| Recurrence | 2 | 2021 | 1419 | 0.210 |
Why?
|
| Calculi | 1 | 2022 | 15 | 0.210 |
Why?
|
| Propensity Score | 1 | 2024 | 211 | 0.210 |
Why?
|
| Lithotripsy | 1 | 2022 | 22 | 0.210 |
Why?
|
| Rectum | 1 | 2023 | 97 | 0.200 |
Why?
|
| Postoperative Care | 1 | 2024 | 295 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3369 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 228 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2393 | 0.200 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 223 | 0.200 |
Why?
|
| Cyst Fluid | 1 | 2021 | 6 | 0.190 |
Why?
|
| Gastroscopy | 1 | 2022 | 102 | 0.190 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 5039 | 0.190 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2021 | 4 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1593 | 0.190 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 255 | 0.190 |
Why?
|
| Japan | 2 | 2018 | 132 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 113 | 0.180 |
Why?
|
| Chronic Pain | 1 | 2022 | 127 | 0.180 |
Why?
|
| Anemia | 1 | 2024 | 340 | 0.170 |
Why?
|
| Equipment Design | 2 | 2024 | 604 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 236 | 0.170 |
Why?
|
| Time Factors | 3 | 2020 | 6219 | 0.160 |
Why?
|
| Bile Ducts | 1 | 2019 | 54 | 0.160 |
Why?
|
| Endoscopes | 1 | 2019 | 20 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 299 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 208 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 216 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 164 | 0.150 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2018 | 16 | 0.150 |
Why?
|
| Triglycerides | 1 | 2021 | 561 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2018 | 140 | 0.150 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 64 | 0.140 |
Why?
|
| Cecum | 1 | 2017 | 27 | 0.140 |
Why?
|
| Ulcer | 1 | 2017 | 48 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 152 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 389 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 235 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 303 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 157 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 268 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2112 | 0.130 |
Why?
|
| Adolescent | 5 | 2018 | 19094 | 0.130 |
Why?
|
| Jaundice | 1 | 2016 | 27 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1236 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 641 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 676 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2017 | 191 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2018 | 376 | 0.110 |
Why?
|
| Survival Rate | 1 | 2019 | 1999 | 0.110 |
Why?
|
| Esophageal Sphincter, Lower | 2 | 2024 | 11 | 0.110 |
Why?
|
| Young Adult | 3 | 2018 | 8854 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2839 | 0.110 |
Why?
|
| Texas | 3 | 2017 | 3563 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 626 | 0.110 |
Why?
|
| Liver | 2 | 2022 | 1734 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2016 | 306 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1688 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1876 | 0.100 |
Why?
|
| Hemorrhage | 2 | 2023 | 458 | 0.100 |
Why?
|
| United States | 5 | 2024 | 10651 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2012 | 56 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 470 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2014 | 1242 | 0.090 |
Why?
|
| Enterotoxins | 1 | 1990 | 82 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 786 | 0.080 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2009 | 65 | 0.080 |
Why?
|
| Mercury Poisoning | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 147 | 0.080 |
Why?
|
| Inhalation Exposure | 1 | 2009 | 36 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 669 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 1990 | 175 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2012 | 383 | 0.080 |
Why?
|
| Retinitis Pigmentosa | 1 | 2009 | 84 | 0.080 |
Why?
|
| Music Therapy | 1 | 2008 | 7 | 0.080 |
Why?
|
| Eye Proteins | 1 | 2009 | 217 | 0.080 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 42 | 0.080 |
Why?
|
| Diarrhea | 1 | 1990 | 315 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2008 | 67 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 1990 | 303 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 434 | 0.070 |
Why?
|
| Bacteroides Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Bacteroides fragilis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Spondylitis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 115 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 84 | 0.070 |
Why?
|
| Colitis | 1 | 2009 | 151 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2024 | 65 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1306 | 0.070 |
Why?
|
| Warfarin | 1 | 2008 | 118 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 108 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2012 | 501 | 0.070 |
Why?
|
| Infant | 3 | 2018 | 12356 | 0.070 |
Why?
|
| Rats | 2 | 2023 | 3651 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 261 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 13887 | 0.060 |
Why?
|
| Inflammation | 2 | 2023 | 1403 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8106 | 0.060 |
Why?
|
| Escherichia coli | 1 | 1990 | 983 | 0.060 |
Why?
|
| North America | 1 | 2024 | 239 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 1739 | 0.060 |
Why?
|
| Albumins | 1 | 2024 | 88 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2023 | 56 | 0.050 |
Why?
|
| Pancreatic Hormones | 1 | 2023 | 4 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2023 | 47 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 45 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 581 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 280 | 0.050 |
Why?
|
| Disaccharides | 1 | 2022 | 13 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 147 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 261 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 607 | 0.050 |
Why?
|
| Child | 3 | 2018 | 24227 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 429 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 327 | 0.050 |
Why?
|
| Models, Animal | 1 | 2023 | 464 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 321 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2022 | 225 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 163 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 211 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 257 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2020 | 28 | 0.040 |
Why?
|
| Manometry | 1 | 2020 | 48 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 792 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 70 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 533 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 294 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 330 | 0.040 |
Why?
|
| Bile | 1 | 2019 | 46 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 678 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 402 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7138 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 347 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 257 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 469 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 63 | 0.040 |
Why?
|
| Optical Fibers | 1 | 2019 | 17 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 44 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 115 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 491 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 2028 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 46 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 84 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 133 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2022 | 4699 | 0.040 |
Why?
|
| Smoking | 1 | 2023 | 1030 | 0.040 |
Why?
|
| Esophagus | 1 | 2019 | 214 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1232 | 0.040 |
Why?
|
| Resuscitation | 1 | 2019 | 244 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2008 | 348 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 423 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3664 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4283 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 33792 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3039 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 4493 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 848 | 0.020 |
Why?
|
| Malaysia | 1 | 1990 | 13 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1990 | 53 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 33 | 0.020 |
Why?
|
| Dark Adaptation | 1 | 2009 | 38 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1990 | 87 | 0.020 |
Why?
|
| Electroretinography | 1 | 2009 | 114 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 2943 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2799 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2009 | 84 | 0.020 |
Why?
|
| Visual Fields | 1 | 2009 | 133 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 581 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2008 | 63 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 87 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 697 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 147 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 794 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 358 | 0.020 |
Why?
|
| Metronidazole | 1 | 2007 | 154 | 0.020 |
Why?
|
| Cross Infection | 1 | 2008 | 330 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2009 | 808 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1583 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 475 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 266 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1288 | 0.010 |
Why?
|